Login
CDT Equity Inc. logo

CDT Equity Inc.

cdtequity.com

What Do They Do?

Develops clinical-stage drug candidates and solid-form compounds for licensing to pharmaceutical and biotechnology companies.

How Do They Make Money?

No revenue reported yet.

Who Are Their Customers?

The company expects pharmaceutical and biotechnology companies to license assets for further development and commercialization; strategic partners may handle sales, marketing and distribution.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +36% (Loss)
vs −$7.1M in Q3 FY2025
  • Nov 5, 2026 Former CEO proposes buying all company shares The proposal is non-binding; the board plans to form a committee to evaluate it.
  • Aug 28, 2026 James Bligh becomes CEO as Andrew Regan resigns Bligh also continues as CFO until a successor is named.

From blank-check search to drug development The older report describes a blank-check company seeking a business combination, focused on real-estate and property-technology targets. The latest report describes developing clinical-stage drug assets, using solid-form chemistry and artificial intelligence, and seeking third-party licenses.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support